

Amendments to the Claims

Please amend claims 2 and 16. This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)
2. (Currently Amended) An antisense oligonucleotide directed against vascular endothelial growth factor (VEGF) wherein said antisense oligonucleotide comprises a plurality of phosphorothioate moieties and has a sequence selected from the group consisting of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 28 and 29, wherein said antisense oligonucleotide inhibits proliferation of Kaposi's Sarcoma cells.
- 3-8. (Canceled)
9. (Previously presented) The antisense oligonucleotide of Claim 2 wherein said antisense oligonucleotide inhibits proliferation of cultured ovarian carcinoma cells at an IC_{50} concentration of less than or equal to about 2 micromolar.
10. (Previously presented) The antisense oligonucleotide of Claim 9 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 9, 10, 13, 14, 17, 28 and 29.
11. (Previously presented) The antisense oligonucleotide of Claim 2 wherein said antisense oligonucleotide inhibits proliferation of cultured melanoma cells at an IC_{50} concentration of less than or equal to about one micromolar.
12. (Previously presented) The antisense oligonucleotide of Claim 11 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 12, 13, 14, and 17.
- 13-15. (Canceled)
16. (Currently amended) A composition formulated for administration to a human, the composition comprising:

- a) an antisense oligonucleotide directed against vascular endothelial growth factor (VEGF) wherein said oligonucleotide comprises a plurality of phosphorothioate moieties and has a sequence selected from the group consisting of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 28 and 29, wherein said antisense oligonucleotide inhibits proliferation of Kaposi's Sarcoma cells; and
- b) a pharmacologically acceptable carrier.

17-19. (Canceled)

20. (Previously presented) The composition of Claim 16 wherein said antisense oligonucleotide is encapsulated in a liposome.

21. (Previously presented) The composition of Claim 16 further comprising an antibody that specifically interacts with a vascular endothelial growth factor or a vascular endothelial growth factor receptor.

22. (Previously presented) The composition of Claim 21 wherein said antibody is specific for Flt-1.

23. (Previously presented) The composition of Claim 21 wherein said antibody is specific for Flk-1.

24. (Previously presented) The composition of Claim 16 further comprising a second antisense oligonucleotide selected from the group consisting of SEQ ID NOS: 1-29.

25. (Previously presented) The composition of Claim 24 wherein said first and second oligonucleotides are encapsulated in a liposome.